Dr. Elizabeth M. JaffeePCP Chair
Dr. Elizabeth M. Jaffee is an internationally recognized expert in cancer immunology and pancreatic cancer. She is deputy director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, codirector of the Skip Viragh Pancreatic Cancer Center, and associate director of the Bloomberg Kimmel Institute for Cancer Immunotherapy. Dr. Jaffee is a past president of the American Association for Cancer Research. She has served on a number of committees at the National Cancer Institute, including as cochair of the Cancer Moonshot Blue Ribbon Panel and as past chair of the National Cancer Advisory Board. Her research is focused on understanding the inflammatory responses that are associated with cancer development and progression in preclinical and clinical models, and development of immunotherapies to treat specific inflammatory signals. She is the inaugural director of the new Convergence Institute at Johns Hopkins and was recently elected to the National Academy of Medicine. Dr. Jaffee is a fellow of the Academy of Immuno-Oncology, the American Association for the Advancement of Science, the American Association of Cancer Research, and the American College of Physicians. She received her undergraduate degree from Brandeis University and her medical degree from New York Medical College and completed her residency at Presbyterian-University Hospital.
Dr. Mitchel S. BergerPCP Member
Dr. Mitchel S. Berger is a neurosurgeon, director of the Brain Tumor Center, and principal investigator for the SPORE (Specialized Program of Research Excellence) Brain Tumor Program at the University of California San Francisco (USCF). He chaired the department of neurological surgery at USCF for 23 years and served on the Cancer Moonshot Blue Ribbon Panel in 2016. He has been funded by the National Cancer Institute to conduct basic science research in brain tumor biology, including the molecular markers that determine the growth and treatment patterns of these tumors. Dr. Berger’s research and clinical work focuses on surgical treatments of brain tumors and tumor-associated epilepsy. He was instrumental in developing brain mapping techniques to identify sites of motor, sensory, and language function to minimize the morbidity associated with tumor surgery. He served as president of two leading national organizations, the American Association of Neurological Surgeons and the Society of Neuro-Oncology. He received his undergraduate degree from Harvard University and his medical degree from the University of Miami School of Medicine, and completed his residency at UCSF’s neurosurgical residency program.
Dr. Carol L. BrownPCP Member
Dr. Carol L. Brown is a gynecologic cancer surgeon and chief health equity officer at Memorial Sloan Kettering Cancer Center, where she holds the Nicholls-Biondi chair for health equity and is vice chair of health equity in the department of surgery. She received her undergraduate degree from Harvard and her medical degree from Columbia, and completed her clinical and research fellowships in gynecologic oncology at Memorial Sloan Kettering. Dr. Brown’s research, clinical, and advocacy work is focused on reducing and eliminating disparities experienced by medically underserved people affected by cancer. She developed and leads the Cancer Health Equities Research Program, a unique partnership between an NCI-designated Cancer Center and community oncologists that brings clinical trials and cancer genomic profiling to underserved patients at their local institutions. In recognition of her contributions, she was awarded the 2017 Minorities in Cancer Research American Association for Cancer Research Jane Cooke Wright Memorial Lectureship. Dr. Brown served as the 50th president of the Society of Gynecologic Oncology and is currently a member of the Board of Regents of the American College of Surgeons.
The Panel accomplishes its mission by identifying high-priority topics for which actionable recommendations can be made, convening meetings with key experts and stakeholders to develop an understanding of the problems, challenges, opportunities, and potential solutions and then framing possible recommendations, including actions that should be taken by relevant organizations. Following substantial input, the Panel submits a report to the President of the United States.
The Panel communicates its findings using a variety of tools—including print and web-based reports, social media, and presentations to a range of organizations. While reports are to the President, they are also for the larger group of stakeholders, public and private, that form the National Cancer Program as well as other partner organizations. Together, these organizations and others can make a positive difference in accelerating progress against cancer.